Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116365 | 0.90 | LRRK2 (0.46) | S1PR1LRRK2 | |
| SCHEMBL20117135 | 0.88 | S1PR1 (0.36) | HDAC8DGAT1S1PR1PTGER3LRRK2 | |
| SCHEMBL20116529 | 0.88 | FASN (0.37) | HDAC8DGAT1S1PR1PTGER3LRRK2 | |
| SCHEMBL20116454 | 0.85 | S1PR1 (0.43) | HDAC8S1PR1 | |
| SCHEMBL22358259 | 0.85 | MAPT (0.51) | MAPTSMN1; SMN2NPC1LMNAHTT | |
| SCHEMBL22358046 | 0.84 | HDAC1 (0.38) | HDAC8DGAT1S1PR1PTGER3MAPT | |
| SCHEMBL20116238 | 0.84 | S1PR1 (0.38) | HDAC8DGAT1S1PR1PTGER3 | |
| SCHEMBL20116074 | 0.83 | PIK3CA (0.37) | DGAT1S1PR1SMOLRRK2MAPT | |
| SCHEMBL20116506 | 0.83 | SMO (0.42) | PTGER3SMOSMN1; SMN2NPC1LMNA | |
| SCHEMBL20116176 | 0.83 | DGAT1 (0.36) | DGAT1S1PR1SMOLRRK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HDAC8 1157/4885DGAT1 3020/4885S1PR1 2213/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | HDAC8 1157/4885DGAT1 3020/4885S1PR1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.